# Corcept Therapeutics says it plans to resubmit its new drug application to the FDA.

*biotech · news · 2026-05-27 · MarketScreener*

## Key points

- Corcept Therapeutics will resubmit its NDA for relacorilant, a Cushing's Syndrome treatment.
- The FDA previously requested more evidence of relacorilant's effectiveness before approval consideration.
- Corcept conducted additional analyses of NDA data at the FDA's request.
- The company plans to resubmit the NDA in the coming weeks after positive analysis results.

By Connor Hart Corcept Therapeutics said it plans to resubmit its new drug application, or NDA, to the Food and Drug Administration for its treatment for hypercortisolism, also known as Cushing's Syndrome. The resubmission comes after the FDA in December said it required more evidence of effectiveness to support the application of the drug, called relacorilant. "Following issuance of its complete response letter, the FDA asked us to conduct additional analyses of our NDA data," Corcept Chief Executive Joseph Belanoff said Wednesday. "Based on the positive outcome of those analyses and the productive tenor of our discussions, we plan to resubmit our NDA in the coming weeks." He added that Corcept has appreciated the FDA's continued engagement throughout the process. Shares climbed 6%, to $64, in premarket trading. Write to Connor Hart at connor.hart@wsj.com (END) Dow Jones Newswires 05-27-26 0858ET

**Companies:** Corcept Therapeutics
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/corcept-plans-to-resubmit-cushing-s-syndrome-drug-application-to-fda-ce7f5ad3d88af22c)

---

Canonical: https://newsio.io/n/1c316e10-41d4-4f9b-9ab8-d43cc5a6be4c/corcept-therapeutics-says-it-plans-to-resubmit-its-new-drug-application-to-the-f
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works